CorporateInformation.com
 
Company Search:
Advanced Search
 
Sponsored Links
 
 
 
 
 
 
 
Anhui Anke Biotechnology (Group) Company., Limited Company Snapshot
Anhui Anke Biotechnology (Group) Company., Limited operates within the Biological products exc. diagnostic sector. In addition to historical fundamental analyses, the complete report available to purchase compares Anhui Anke Biotechnology (Group) Company., Limited with three other companies in this sector in CHINA : Jinyu Bio-Technology Co Ltd (2020 sales of 1.58 billion Chinese Renmimbi [US$246.10 million] of which 96% was Bio-Pharmaecutical), Vcanbio Cell & Gene Engineering Corp Ltd (1.32 billion Chinese Renmimbi [US$204.88 million] of which 61% was Manufacturing), and Tianjin Ringpu Bio-Technology Co Ltd (2.00 billion Chinese Renmimbi [US$311.20 million] of which 56% was Veterinary Biological Products).

Sales Analysis. During the second quarter of 2021, sales at Anhui Anke Biotechnology (Group) Company., Limited totalled 479.84 million Chinese Renmimbi. This is an increase of 20.5% from the 398.28 million Chinese Renmimbi in sales at the company during the second quarter of 2020. During the first two quarters of 2021, sales totalled 969.24 million Chinese Renmimbi, which is 35.6% higher than through the first two quarters of 2020. Sales at Anhui Anke Biotechnology (Group) Company., Limited appear to have some seasonality: during each of the previous 9 years, sales have been highest during the fourth quarter, which has accounted for between 27.9% and 32.8% of the annual sales. During the year ended December of 2020, sales at Anhui Anke Biotechnology (Group) Company., Limited were 1.70 billion Chinese Renmimbi (US$264.69 million). This is a decrease of 0.6% versus 2019, when the company's sales were 1.71 billion Chinese Renmimbi. Contributing to the drop in overall sales was the 23.7% decline in Raw Material Medicine, from 77.68 million Chinese Renmimbi to 59.26 million Chinese Renmimbi. There were also decreases in sales in Medicine (down 6.9% to 456.27 million Chinese Renmimbi) and Chemical Synthetic Drugs (down 0.5% to 126.25 million Chinese Renmimbi) and Technical Services (down 10.6% to 117.80 million Chinese Renmimbi) . However, these declines were partially offset by the increase in sales of Biological Products (up 4.0% to 895.38 million Chinese Renmimbi) and Others (up 87.3% to 46.46 million Chinese Renmimbi) .
   
   
 
Company ReportsSubscriptions
 
Looking For More?
Purchace an In-Depth Report
Anhui Anke Biotechnology (Group) Company., Limited
  Stock Performance Chart for Anhui Anke Biotechnology (Group) Company., Limited
 
  Stock Data: Recent Stock Performance:
  Current Price (10/8/2021): 12.45
(Figures in Chinese Renmimbi)
1 Week 4.2%   13 Weeks 1.4%  
4 Weeks -16.2%   52 Weeks -9.8%  
 
Anhui Anke Biotechnology (Group) Company., Limited Key Data:
  Ticker: 300009 Country: China
  Exchanges: SZN Major Industry: Pharmaceuticals & Biotechnology
    Sub Industry: Biological Products Exc. Diagnostic
  2020 Sales 1,701,417,216
(Year Ending Jan 2021).
Employees: 2,384
  Currency: Chinese Renmimbi Market Cap: 20,398,896,197
  Fiscal Yr Ends: December Shares Outstanding: 1,638,465,558
  Share Type: A Gu Closely Held Shares:
 
 
Sponsored Links
 
 
 
 
Feedback | Terms and Conditions | Privacy Policy | Site Index
 
CorporateInformation® website and selected data Copyright © 2000 - by The Winthrop Corporation. All Rights Reserved. Except for quotations by established news media, no pages on this site may be reproduced, stored in a retrieval system, or transmitted for commercial purposes, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without prior written permission. Information is believed reliable, but accuracy, completeness and opinions are not guaranteed.